# A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

> **NCT02723539** · PHASE1 · COMPLETED · sponsor: **Microbion Corporation** · enrollment: 52 (actual)

## Conditions studied

- Diabetic Foot Infection

## Interventions

- **DRUG:** MBN-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02723539
- **Lead sponsor:** Microbion Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-06
- **Primary completion:** 2017-11-01
- **Final completion:** 2019-07-26
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723539, "A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT02723539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*